Clinical trials: Metformin
Diabetes Mellitus, Type 2
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
- Trial name
- NCT00135330
- Testing
- exenatide, rosiglitazone
- Where
- 19 sites in United States
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Psoriasis, Plaque Psoriasis
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial conducted in China. The study aims to evaluate the efficacy and safety of metformin combined with secukinumab in the treatment of…
- Conditions
- Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis, Overweight , Obesity
- Trial name
- NCT07485764
- Testing
- Secukinumab 300mg s.c., Metformin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metabolic Syndrome
Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome
Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of living cells and is widespread in many food.
- Trial name
- NCT01046500
- Testing
- myo-inositol, Metformin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Messina
Metabolic Syndrome
Metformin in Postmenopausal Women With Metabolic Syndrome
The purpose of this study is to determine the effects of metformin on cardiovascular risk factors in postmenopausal women with metabolic syndrome.
- Trial name
- NCT01342744
- Testing
- Metformin
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Pre-Eclampsia
Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia
Preeclampsia is globally responsible for tens of thousands of maternal and neonatal deaths each year. Currently, there are no medical therapies to halt disease progression and expectant management and delivery remain the mainstay…
- Trial name
- NCT03717701
- Testing
- metformin, esomeprazole
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Aswan University Hospital
Diabetes Mellitus
DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)
1. Many patients with type 2 diabetes are not at glycaemic goal and require additional therapy in order to reduce vascular risk and improve symptom control 2.
- Trial name
- DiaFrail (NCT02484209)
- Testing
- Metformin, Glimepiride
- Sponsor
- Diabetes Frail Ltd
Type 2 Diabetes Mellitus
Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment
Dose-ranging study of AVE2268 in the management of patients with type 2 diabetes mellitus also receiving metformin. Its main objectives will be to assess the effects of several doses of AVE2268 on Mean Plasma Glucose.
- Trial name
- NCT00361738
- Testing
- AVE2268
- Where
- 11 sites in Argentina, Australia and 9 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318109
- Testing
- Alogliptin and metformin, Metformin
- Volunteers
- 288 people
- Sponsor
- Takeda
Heart Failure, Systolic
Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure
The study evaluates the effects of metformin treatment on myocardial efficiency in heart failure patients. 36 patients will be randomized to three months of metformin or placebo treatment in addition to their regular therapy.
- Trial name
- METRONOME (NCT02810132)
- Testing
- Metformin
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Aarhus University Hospital
Non Small Cell Lung Cancer, Lung Cancer
Phase II Lung Metcore - Preoperative Metformin for Lung Cancer
This is a phase II single centre open label single arm pre-operative window of metformin treatment in stage I-IIIa Non small cell lung cancer.
- Trial name
- Metcore (NCT03086733)
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Human Microbiome
A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles
This clinical trial is intended to evaluate the effect of change of bile acid pool with cholestyramine on the pharmacodynamics and safety of metformin and intestinal microbiome profiles in healthy volunteers
- Trial name
- NCT04335526
- Testing
- Cholestyramine Resin
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs
The purpose of this study is to compare the safety and pharmacokinetic characteristics of fixed-dose combination of MP-513 20mg and Metformin XR 1000mg with coadministration of the two separate drugs in healthy male volunteers.
- Trial name
- NCT03787017
- Testing
- FDC(MP-513 20mg/Metformin XR 1000mg), MP-513 20mg, Metformin XR 1000mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Type 2 Diabetes Mellitus
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT02033889
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Glimepiride
- Volunteers
- 621 people
- Sponsor
- Merck Sharp & Dohme LLC
Polycystic Ovary Syndrome, Obesity
Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug.
- Trial name
- NCT02909933
- Testing
- liraglutide, metformin and liraglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
- Trial name
- NCT01059825
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 375 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions
The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company…
- Trial name
- NCT00865852
- Testing
- Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Polycystic Ovary Syndrome
PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene
1. Metformin increases the pregnancy rate when added to the standard treatment of anovulatory polycystic ovary syndrome (PCOS). 2.
- Trial name
- PCOSMIC (NCT00795808)
- Testing
- Metformin, Metformin + Clomiphene, Clomiphene
- Where
- New Zealand
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- University of Auckland, New Zealand
Healthy
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers
The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC) tablets of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and metformin…
- Trial name
- NCT01454622
- Testing
- A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.